Moreover, when added to the clinical base model, FGF-23 provided incremental value for predicting CV death or HF to validated clinical predictors and multiple biomarkers, including eGFR, BNP, hs-CRP, and hs-cTnI [76]. The gene discussed is NPPB; the disease is hydrops fetalis.